查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466286

伴同性診斷市場：按技術、適應症和最終用戶分類 - 2024-2030 年全球預測

Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

伴同性診斷市場規模預計2023年為66.4億美元，2024年達73億美元，預計2030年將達到134.9億美元，複合年成長率為10.65%。

伴同性診斷是專門的測試，旨在幫助醫療保健專業人員確定特定的醫療程序對患者是否有效，並確定該個體的最佳劑量。這些測試是個人化醫療的重要組成部分，個人化醫療是一種根據每個患者的個人特徵（包括生活方式、遺傳傾向和環境）提供量身定做治療的醫療方法。伴同性診斷被廣泛使用，特別是在某些癌症的治療中，其中治療效果可能會受到腫瘤內存在的遺傳改變的極大影響。個人化醫療的發展，即根據患者個別情況最佳化治療，是伴同性診斷需求的主要驅動力。此外，標靶治療的開發，特別是在腫瘤學領域，需要伴同性診斷來識別將從這些治療中受益最多的患者。然而，開發和引入伴同性診斷的成本高昂，報銷不足是一個主要障礙。此外，次世代定序和數位 PCR 等技術正在擴展伴同性診斷的能力，並實現更全面的基因分析，為市場成長提供了巨大的機會。

主要市場統計
基準年[2023] 66.4億美元
預測年份 [2024] 73億美元
預測年份 [2030] 134.9億美元
複合年成長率（%） 10.65%

科技 精準醫療領域對次世代定序儀的偏好日益增加

免疫組織化學 (IHC) 是一種透過檢測組織切片中細胞中的蛋白質來診斷疾病的技術。它廣泛用於癌症診斷，以識別有助於確定癌症類型及其對治療的潛在反應的特異性標記。當診斷重點是組織樣本中蛋白質表現的定位和定性評估時，首選 IHC。原位雜合技術 (ISH) 能夠檢測和定位組織切片或細胞樣本中的特定 DNA 或 RNA 序列，從而深入了解基因表現和染色體畸變。該技術在檢測與某些癌症相關的特定基因重排和擴增方面特別有用。次世代定序儀(NGS) 透過以前所未有的速度和規模對整個基因組或感興趣區域進行定序，提供對基因組成的全面洞察。 NGS 是需要廣泛了解遺傳變異（包括小突變、拷貝數變異等）的應用的首選技術，這些變異可能與多種疾病的標靶治療選擇相關。聚合酵素鏈鎖反應(PCR) 是一種用於增強 DNA 或 RNA 小片段以促進進一步分析的技術。 PCR 由於其簡單性、敏感性和特異性而成為最廣泛使用的技術之一。 PCR 因其快速處理時間而備受青睞，使其成為需要快速決策以選擇治療方法的疾病的理想選擇。

最終用戶製藥和生物製藥領域的擴展推動了伴同性診斷的重要性

製藥和生物製藥公司主要從事治療藥物的發現、開發和商業化。伴同性診斷的整合在標靶治療治療的開發過程中至關重要，特別是在癌症治療中。這些公司需要伴同性診斷來監測治療反應並根據需要調整治療計劃。參考文獻實驗室是執行複雜且先進的診斷測試的專業設施，而標準醫院實驗室通常無法提供這些測試。它們透過提供複雜的測試來幫助識別與特定疾病和治療反應相關的生物標記物，在實施伴同性診斷中發揮重要作用。

區域洞察

在美洲，強大的醫療基礎設施、日益​​增強的個人化醫療意識以及重要的研發活動推動了對伴同性診斷的需求。美國食品藥物管理局(FDA) 在核准癌症治療伴同性診斷方面特別積極，並強調了這些工具在治療決策中的重要性。該地區的投資和舉措主要集中在癌症、心血管疾病和神經病學領域，反映出個人化醫療解決方案的更廣泛趨勢。歐盟國家對伴同性診斷表現出很高的需求，並得到強力的法律規範促進創新，同時確保病人安全。歐洲藥品管理局 (EMA) 在整個歐洲核准伴同性診斷方面發揮關鍵作用。歐盟消費者的需求複雜，對個人化醫療服務抱有很高的期望。在阿拉伯聯合大公國和沙烏地阿拉伯等中東國家，在政府措施和醫療基礎設施投資的支持下，人們對個人化醫療的興趣與日俱增。然而，由於衛生基礎設施和服務有限，非洲面臨重大障礙。在亞太地區，在政府旨在普及醫療保健標準和促進個人化醫療的舉措的推動下，伴同性診斷市場正在迅速擴大。政府推出了多項推動精準醫療的舉措，包括對基因研究的大量投資。這種關注逐漸體現在對伴同性診斷不斷成長的需求上，尤其是在設備齊全的都市區。

FPNV定位矩陣

FPNV 定位矩陣對於評估伴同性診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對伴同性診斷市場中供應商的現狀進行富有洞察力和深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.伴同性診斷市場的市場規模和預測是多少？

2.在伴同性診斷市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.伴同性診斷市場的技術趨勢和法規結構是什麼？

4.伴同性診斷市場主要廠商的市場佔有率為何？

5.進入伴同性診斷市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 伴同性診斷在藥物開發中的重要性日益增加
      • 對個人化藥物和標靶治療的需求增加
      • 加強次世代定序創新的研究與開發
    • 抑制因素
      • 開發和實施伴同性診斷的高成本
    • 機會
      • 診斷技術的持續技術進步
      • 有利的監管政策促進伴同性診斷的開發和核准
    • 任務
      • 與伴同性診斷測試相關的報銷問題
  • 市場區隔分析
    • 技術：次世代定序在精準醫療中受到歡迎
    • 最終用戶：製藥和生物製藥行業的擴張推動了伴同性診斷的重要性
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章伴同性診斷市場：依技術分類

  • 免疫組織化學
  • 原位雜合技術
  • 次世代定序
  • 聚合酵素鏈鎖反應

第7章按適應症分類的伴同性診斷市場

  • 癌症
  • 心血管疾病
  • 感染疾病
  • 神經系統疾病

第8章伴同性診斷市場：依最終用戶分類

  • 製藥和生物製藥公司
  • 參考實驗室

第9章美洲伴同性診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區伴同性診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲伴同性診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Thermo Fisher Scientific 與拜耳的創新合作為精準癌症治療樹立了新標準
    • 安捷倫與 Insight 結成策略聯盟，加速伴同性診斷的發展
    • 開闢新的治療視野：FDA核准Capivasertib 和氟維司群聯合治療進行性乳癌，支持 FoundationOne® CDx 診斷的進步
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-433AB1DC2871

[194 Pages Report] The Companion Diagnostics Market size was estimated at USD 6.64 billion in 2023 and expected to reach USD 7.30 billion in 2024, at a CAGR 10.65% to reach USD 13.49 billion by 2030.

Companion diagnostics are specialized tests designed to help healthcare professionals determine whether a particular medical treatment is effective for a patient or to identify the best dosage of medication for that individual. These tests are an integral part of personalized medicine, a medical approach that tailors treatment to the individual characteristics of each patient, such as their lifestyle, genetic makeup, and environment. Companion diagnostics are particularly prevalent in the management of certain cancers, where the effectiveness of the treatment can depend significantly on the genetic alterations present within the tumor. The push towards personalized medicine, where treatments are optimized for individual patient profiles, significantly drives the demand for companion diagnostics. Moreover, the development of targeted therapies, especially in oncology, necessitates companion diagnostics to identify patients who would most benefit from these treatments. However, the development and implementation of companion diagnostics can be costly, with inadequate reimbursement posing a significant barrier. Furthermore, technologies, including next-generation sequencing and digital PCR, are expanding the capabilities of companion diagnostics, allowing for more comprehensive genetic profiling poses significant opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 6.64 billion
Estimated Year [2024] USD 7.30 billion
Forecast Year [2030] USD 13.49 billion
CAGR (%) 10.65%

Technology: Increasing preference of next-generation sequencing in precision medicine

Immunohistochemistry (IHC) is a technique used to diagnose diseases by detecting proteins in tissue section cells. It is widely employed in cancer diagnostics to identify specific markers that help in determining the type of cancer and its potential responsiveness to treatments. IHC is preferred when the diagnostic focus is on the localization and qualitative assessment of protein expressions in tissue samples. Situ Hybridization (ISH) permits the detection and localization of specific DNA or RNA sequences in tissue sections or cell samples, providing insights into gene expression and chromosomal abnormalities. This technology is particularly valuable in detecting specific gene rearrangements or amplifications associated with certain cancers. Next-generation sequencing (NGS) offers comprehensive insights into the genetic makeup by allowing the sequencing of entire genomes or targeted regions of interest at an unprecedented speed and scale. NGS is the technology of choice for applications requiring a broad understanding of genetic variations, including small mutations, copy number variations, and others that may be relevant for selecting targeted therapies across various diseases. Polymerase Chain Reaction (PCR) is a technique utilized to strengthen small segments of DNA or RNA, making it easier to conduct further analyses. It stands as one of the most widely used technologies due to its simplicity, sensitivity, and specificity. PCR is highly favored for its rapid turnaround times, making it ideal for diseases requiring quick decision-making for therapy selection.

End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics

Pharmaceutical and biopharmaceutical companies engaged primarily in the discovery, development, and commercialization of therapeutics. The integration of companion diagnostics is crucial in the drug development process, especially for targeted therapies, including those used in cancer treatment. These companies need companion diagnostics to monitor responses to therapy and adjust treatment plans as necessary. Reference laboratories are specialized facilities that perform complex and advanced diagnostic testing, often not available in standard hospital labs. They play a critical role in the implementation of companion diagnostics by providing high-complexity tests that help in the identification of biomarkers associated with specific diseases and treatment responses.

Regional Insights

In the Americas, the demand for companion diagnostics is driven by a robust healthcare infrastructure, heightened awareness about personalized medicine, and significant research and development activities. The U.S. Food and Drug Administration (FDA) has been proactive in approving companion diagnostics, especially for cancer treatments, which underscores the importance of these tools in therapeutic decisions. Investments and initiatives in this region are primarily focused on oncology, cardiovascular diseases, and neurology, reflecting a broader trend toward personalized healthcare solutions. EU countries exhibit a high demand for companion diagnostics, supported by a strong regulatory framework that promotes innovation while ensuring patient safety. The European Medicines Agency (EMA) plays an vital role in the approval of companion diagnostics across Europe. Consumer needs in the EU are sophisticated, with a high expectation for personalized healthcare services. Middle Eastern countries, such as the United Arab Emirates and Saudi Arabia, are witnessing a growing interest in personalized medicine, which is supported by government initiatives and investments in healthcare infrastructure. Africa, however, faces significant hurdles due to limited healthcare infrastructure and access. In APAC, the market for companion diagnostics is expanding swiftly, fueled by government initiatives aimed at improving healthcare standards and embracing personalized medicine. The government has launched several initiatives to promote precision medicine, including significant investments in genetic research. This focus is gradually translating into increased demand for companion diagnostics, particularly in urban areas with better healthcare facilities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Companion Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Companion Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMerieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Immunohistochemistry
    • In Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Indication
    • Cancer
      • Blood Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurological Disorders
  • End-user
    • Pharmaceutical & Biopharmaceutical Companies
    • Reference Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Companion Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Companion Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Companion Diagnostics Market?

4. What is the market share of the leading vendors in the Companion Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Companion Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing significance of companion diagnostics in drug development
      • 5.1.1.2. Increasing demand for personalized medicines and targeted therapy
      • 5.1.1.3. Rise in research and development for innovation in next generation sequencing
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with development and implementation of companion diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in diagnostic techniques
      • 5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues associated with companion diagnostic tests
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
    • 5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Companion Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunohistochemistry
  • 6.3. In Situ Hybridization
  • 6.4. Next-Generation Sequencing
  • 6.5. Polymerase Chain Reaction

7. Companion Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular Diseases
  • 7.4. Infectious Diseases
  • 7.5. Neurological Disorders

8. Companion Diagnostics Market, by End-user

  • 8.1. Introduction
  • 8.2. Pharmaceutical & Biopharmaceutical Companies
  • 8.3. Reference Laboratories

9. Americas Companion Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Companion Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Companion Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
    • 12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
    • 12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne(R) CDx Diagnostic Advances
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND COMPANION DIAGNOSTICS MA